Close
Platforms
Online Inquiry

CONTACT US

USA:

UK:
Call us at:
USA:
UK:
Fax:
Email:

Animal Model Platform for CAR-T Therapy

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Chimeric antigen receptor (CAR)-engineered T-cell therapy is one of the most promising areas of cancer immunotherapy that has delivered impressive and promising results in the treatment of hematological cancer. With leading expertise and state-of-the-art technology in immunology, Creative Biolabs has established CellRapeutics™ CAR-Technology platform to design improved CAR T-cells for successful tumor elimination while also limiting the development of serious adverse effects.

Though CAR-T therapies have been approved for blood cancers, their application to solid tumors has proved challenging. Preclinical evaluation of CAR-T cell therapy is highly needed. Our scientists have developed a cutting-edge animal model platform to significantly improve the evaluation of CAR-T cell therapy. We are proficient at performing a wide range of preclinical in vivo assays, hoping to answer all your questions through our series of translation models.

Humanized Mouse Models at Creative Biolabs

  • NSG Mouse Model

Testing CAR T-cells for their suitability in the clinic implies the use of immuno-compromised mouse models. Currently, Creative Biolabs mainly provides two research-ready mouse models, CD34+ HSC Hu-NSG Mouse Model and PBMC Hu-NSG Mouse Model, which represent two commonly used methods for generating humanized models. NSG engrafted with human CD34+ hematopoietic stem cells (HSC) can develop multi-lineage human immune cells, and is effective in vivo model for the evaluation of CAR-T therapy research, other immunology research, and infectious disease research. While PBMC Hu-NSG mouse model is generated by injecting human peripheral blood mononuclear cells (PBMC) into female NSG mice, and this model is very suitable for short-term studies that require powerful effectors and memory T cells and NK cell functions.

  • Patient-derived Xenograft (PDX) Model

PDX models have been increasingly used in translational research since their development. Studies have shown that PDX models can produce samples that are authentic to the host tumor, and they can accurately replicate tumor growth, diversity of tumor cells, and tumor progression, including metastatic potential. Creative Biolabs has a highly experienced team of scientists who have a long history of successful implementation of PDX model generation and PDX models for the evaluation of CAR-T therapy.

  • The Flowchart of PDX Model Generation and Evaluation of CAR-T Therapy:
  • Animal Model Platform for CAR-T Therapy

  • Features of PDX Models at Creative Biolabs Including but Not Limited to:
    • Confirmed human origin
    • Complete human pathogen assessment
    • Validation of human DNA content for the entire distribution lot
    • Validated short tandem repeat (STR) profile
    • Quality control by whole-exome sequence (WES) and/or RNASeq

Living Tumor Biobank at Creative Biolabs

Creative Biolabs has collaborated with hospital and researchers to establishes a central repository of >1700 PDX models of various tumors, including lung cancer, colorectal cancer, gastric cancer, pancreatic cancer, breast cancer, ovarian cancer, head & neck cancer, cervical cancer, esophageal cancer, mesothelioma, and metastatic cancer, etc. We also provide high-quality services for the use of PDX models.

Animal Model Platform for CAR-T Therapy

Creative Biolabs has organized a staff of outstanding scientists who have engaged in the preclinical study for CAR-T therapy. Our technologies aim to facilitate the preclinical study for CAR-T therapy research, other immunology research, and infectious disease research. If you are interested in our animal model platform, please contact us for more information and a detailed quote.

References

  1. Siegler, E.L.; Wang, P. Preclinical models in chimeric antigen receptor-engineered T-cell therapy. Human gene therapy. 2018, 29(5): 534-46.
  2. Wegner, A. Chimeric antigen receptor T cells for the treatment of cancer and the future of preclinical models for predicting their toxicities. Immunotherapy. 2017, 9(8): 669-80.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Online Inquiry

For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Key Updates

Receive our latest news and insights.